GlassScriptPhysician profile
Farida S Cheddie
NPI 1780856260
$3,897.65
in general payments reported to CMS, 2019-2025
22 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,046 · 2022: $724 · 2023: $769 · 2024: $689 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,569.82 | 2021-2025 | Mycarelink, Micra, Linq II |
| Janssen Pharmaceuticals, INC | $564.55 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $354.77 | 2021-2025 | General - Therapies |
| Novartis Pharmaceuticals Corporation | $206.23 | 2021-2025 | |
| Amgen INC. | $205.27 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $141.79 | 2021-2025 | Wainua, Farxiga |
| Pfizer INC. | $134.44 | 2022-2024 | |
| Astellas Pharma US INC | $109.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.08 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $86.03 | 2023-2025 | Verquvo |
| Cvrx, INC. | $79.38 | 2022-2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $63.01 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $42.79 | 2022-2025 | Opsumit, Uptravi |
| Abiomed | $37.11 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $33.03 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $29.67 | 2024 | |
| Alnylam Pharmaceuticals INC. | $28.77 | 2023 | Onpattro |
| Baxter Healthcare | $24.52 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $23.38 | 2022 | |
| Terumo Medical Corporation | $21.14 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.87 | 2023 | Arcalyst |
| Genzyme Corporation | $15.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farida Cheddie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.